Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Ruutu T, Hermans J, van Biezen A, Niederwieser D, Gratwohl A, Apperley JF . How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 22: 614–615.

    Article  CAS  Google Scholar 

  2. Bolanos-Meade J, Vogelsang GB . Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol 2005; 12: 40–44.

    Article  CAS  Google Scholar 

  3. Couriel D, Caldera H, Champlin R, Komanduri K . Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004; 101: 1936–1946.

    Article  Google Scholar 

  4. Bacigalupo A, van Lint MT, Frassoni F, Podesta M, Veneziano G, Avanzi G et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut 1983; 46: 125–132.

    Article  CAS  Google Scholar 

  5. Deeg HJ . How I treat refractory acute GVHD. Blood 2007, Prepublished online January 18, 2007: doi 10.1182/blood-2006-12-041889.

  6. Knop S, Hebart H, Gscheidle H, Holler E, Kolb HJ, Niederwieser D et al. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transplant 2005; 36: 831–837.

    Article  CAS  Google Scholar 

  7. Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallorso S et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107: 4177–4181.

    Article  CAS  Google Scholar 

  8. Bruner RJ, Farag SS . Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin Oncol 2003; 30: 509–519.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H Einsele.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knop, S., Hebart, H., Gratwohl, A. et al. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia 21, 1830–1833 (2007). https://doi.org/10.1038/sj.leu.2404731

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404731

This article is cited by

Search

Quick links